Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.

ABSTRACT:

Background

Recent advances in therapeutic interventions have dramatically improved complete response rates in patients with multiple myeloma (MM). The ability to identify residual myeloma cells (e.g., measurable residual disease [MRD]) can provide valuable information pertaining to patient's depth of response to therapy and risk of relapse. Multiparametric flow cytometry is an excellent technique to monitor MRD and has been demonstrated to correlate with patient outcome post-treatment. To achieve the high sensitivity (one abnormal cell in 10⁵ -10⁶ cells) required for MRD evaluation, millions of cells have to be acquired and conventional immunophenotyping protocols are unable to attain these numbers, indicating the needs for alternative flow cytometric staining

SUBMITTER: Soh KT 

PROVIDER: S-EPMC7741435 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature